327 related articles for article (PubMed ID: 28378389)
1. NKG2D stimulation of CD8
Kavazović I; Lenartić M; Jelenčić V; Jurković S; Lemmermann NAW; Jonjić S; Polić B; Wensveen FM
Eur J Immunol; 2017 Jul; 47(7):1123-1135. PubMed ID: 28378389
[TBL] [Abstract][Full Text] [Related]
2. NKG2D: A versatile player in the immune system.
Jelenčić V; Lenartić M; Wensveen FM; Polić B
Immunol Lett; 2017 Sep; 189():48-53. PubMed ID: 28414183
[TBL] [Abstract][Full Text] [Related]
3. NKG2D receptor activation of NF-κB enhances inflammatory cytokine production in murine effector CD8(+) T cells.
Whitman E; Barber A
Mol Immunol; 2015 Feb; 63(2):268-78. PubMed ID: 25089028
[TBL] [Abstract][Full Text] [Related]
4. Cutting Edge: NKG2D Signaling Enhances NK Cell Responses but Alone Is Insufficient To Drive Expansion during Mouse Cytomegalovirus Infection.
Nabekura T; Gotthardt D; Niizuma K; Trsan T; Jenus T; Jonjic S; Lanier LL
J Immunol; 2017 Sep; 199(5):1567-1571. PubMed ID: 28760883
[TBL] [Abstract][Full Text] [Related]
5. CD8 T cells in innate immune responses: using STAT4-dependent but antigen-independent pathways to gamma interferon during viral infection.
Suarez-Ramirez JE; Tarrio ML; Kim K; Demers DA; Biron CA
mBio; 2014 Oct; 5(5):e01978-14. PubMed ID: 25336459
[TBL] [Abstract][Full Text] [Related]
6. Memory CD8 T Cells Generated by Cytomegalovirus Vaccine Vector Expressing NKG2D Ligand Have Effector-Like Phenotype and Distinct Functional Features.
Šustić M; Cokarić Brdovčak M; Lisnić B; Materljan J; Juranić Lisnić V; Rožmanić C; Indenbirken D; Hiršl L; Busch DH; Brizić I; Krmpotić A; Jonjić S
Front Immunol; 2021; 12():681380. PubMed ID: 34168650
[TBL] [Abstract][Full Text] [Related]
7. Acute Virus Control Mediated by Licensed NK Cells Sets Primary CD8+ T Cell Dependence on CD27 Costimulation.
Teoh JJ; Gamache AE; Gillespie AL; Stadnisky MD; Yagita H; Bullock TN; Brown MG
J Immunol; 2016 Dec; 197(11):4360-4370. PubMed ID: 27798162
[TBL] [Abstract][Full Text] [Related]
8. Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity.
Andoniou CE; van Dommelen SL; Voigt V; Andrews DM; Brizard G; Asselin-Paturel C; Delale T; Stacey KJ; Trinchieri G; Degli-Esposti MA
Nat Immunol; 2005 Oct; 6(10):1011-9. PubMed ID: 16142239
[TBL] [Abstract][Full Text] [Related]
9. NKG2D ligation without T cell receptor engagement triggers both cytotoxicity and cytokine production in dendritic epidermal T cells.
Nitahara A; Shimura H; Ito A; Tomiyama K; Ito M; Kawai K
J Invest Dermatol; 2006 May; 126(5):1052-8. PubMed ID: 16484989
[TBL] [Abstract][Full Text] [Related]
10. NKG2D induces Mcl-1 expression and mediates survival of CD8 memory T cell precursors via phosphatidylinositol 3-kinase.
Wensveen FM; Lenartic M; Jelencic V; Lemmermann NA; ten Brinke A; Jonjic S; Polic B
J Immunol; 2013 Aug; 191(3):1307-15. PubMed ID: 23804716
[TBL] [Abstract][Full Text] [Related]
11. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation.
Gilfillan S; Ho EL; Cella M; Yokoyama WM; Colonna M
Nat Immunol; 2002 Dec; 3(12):1150-5. PubMed ID: 12426564
[TBL] [Abstract][Full Text] [Related]
12. Activation of V gamma 9V delta 2 T cells by NKG2D.
Rincon-Orozco B; Kunzmann V; Wrobel P; Kabelitz D; Steinle A; Herrmann T
J Immunol; 2005 Aug; 175(4):2144-51. PubMed ID: 16081780
[TBL] [Abstract][Full Text] [Related]
13. NKG2D is a costimulatory receptor for human naive CD8+ T cells.
Maasho K; Opoku-Anane J; Marusina AI; Coligan JE; Borrego F
J Immunol; 2005 Apr; 174(8):4480-4. PubMed ID: 15814668
[TBL] [Abstract][Full Text] [Related]
14. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells.
Ehrlich LI; Ogasawara K; Hamerman JA; Takaki R; Zingoni A; Allison JP; Lanier LL
J Immunol; 2005 Feb; 174(4):1922-31. PubMed ID: 15699119
[TBL] [Abstract][Full Text] [Related]
15. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells.
Burgess SJ; Marusina AI; Pathmanathan I; Borrego F; Coligan JE
J Immunol; 2006 Feb; 176(3):1490-7. PubMed ID: 16424177
[TBL] [Abstract][Full Text] [Related]
16. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
17. NKG2D blockade facilitates diabetes prevention by antigen-specific Tregs in a virus-induced model of diabetes.
Van Belle TL; Ling E; Haase C; Bresson D; Ursø B; von Herrath MG
J Autoimmun; 2013 Feb; 40():66-73. PubMed ID: 22944096
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cells promote early CD8 T cell responses against cytomegalovirus.
Robbins SH; Bessou G; Cornillon A; Zucchini N; Rupp B; Ruzsics Z; Sacher T; Tomasello E; Vivier E; Koszinowski UH; Dalod M
PLoS Pathog; 2007 Aug; 3(8):e123. PubMed ID: 17722980
[TBL] [Abstract][Full Text] [Related]
19. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells.
Karimi M; Cao TM; Baker JA; Verneris MR; Soares L; Negrin RS
J Immunol; 2005 Dec; 175(12):7819-28. PubMed ID: 16339517
[TBL] [Abstract][Full Text] [Related]
20. Human tumor-derived exosomes down-modulate NKG2D expression.
Clayton A; Mitchell JP; Court J; Linnane S; Mason MD; Tabi Z
J Immunol; 2008 Jun; 180(11):7249-58. PubMed ID: 18490724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
